Pesquisa | Portal de Pesquisa da BVS

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.

Branche, Angela R; Rouphael, Nadine G; Losada, Cecilia; Baden, Lindsey R; Anderson, Evan J; Luetkemeyer, Anne F; Diemert, David J; Winokur, Patricia L; Presti, Rachel M; Kottkamp, Angelica C; Falsey, Ann R; Frey, Sharon E; Rupp, Richard; Bäcker, Martín; Novak, Richard M; Walter, Emmanuel B; Jackson, Lisa A; Little, Susan J; Immergluck, Lilly C; Mahgoub, Siham M; Whitaker, Jennifer A; Babu, Tara M; Goepfert, Paul A; Fusco, Dahlene N; Atmar, Robert L; Posavad, Christine M; Netzl, Antonia; Smith, Derek J; Telu, Kalyani; Mu, Jinjian; Makowski, Mat; Makhene, Mamodikoe K; Sonja, Crandon; Montefiori, David C; Roberts, Paul C; Beigel, John H.

medRxiv ; 2023 Mar 31.

Artigo em Inglês | MEDLINE | ID: mdl-37034641

RESUMO

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Ver mais detalhes

ENVIAR RESULTADO:

Exportar

Imprimir

RSS

XML

RESUMO

ENVIAR RESULTADO:

SELEÇÃO DE REFERÊNCIAS

DETALHE DA PESQUISA